Skip to main content

Table 2 Association between RRM1 , RRM2B, and 2R status and PAM50 intrinsic subtype

From: Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Characteristics RRM1 RRM2B 2R
Normal Aberrant   Normal Aberrant   Normal Aberrant  
No. (%) No. (%) Pa No. (%) No. (%) Pa No. (%) No. (%) Pa
No. of patients 211   40    217   34    184   67   
PAM50 b      0.38      0.0004      0.009
Luminal A 63 (29.9) 8 (20.0)   70 (32.3) 1 (2.9)   62 (33.7) 9 (13.4)  
Luminal B 74 (35.1) 15 (37.5)   75 (34.6) 14 (41.2)   62 (33.7) 27 (40.3)  
Basal-like 32 (15.2) 10 (25.0)   35 (16.1) 7 (20.6)   27 (14.7) 15 (22.4)  
HER2-enriched 37 (17.5) 7 (17.5)   33 (15.2) 11 (32.4)   29 (15.8) 15 (22.4)  
Unknown 5 (0.0) 0 (0.0)   4 (1.8) 1 (2.9)   4 (2.2) 1 (1.5)  
  1. Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM2B both normal, HER2 human epidermal growth factor receptor 2, RRM1 ribonucleotide reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit.
  2. a Fishers exact test, unknown values excluded from tests.
  3. b PAM50: A 50-gene expression classifier that identifies the four major intrinsic subtypes of breast cancer known as the luminal A, luminal B, HER2-enriched and basal-like subtypes [26].